BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing...
BioCentury | Mar 9, 2020
Finance

GenFleet eyes proof of concept with $50M series B

Looking to start its first international and proof-of-concept trials, GenFleet raised more than $50 million in a series B round led by CDH and Shenzhen Capital group. The round saw participation by new investors South...
BioCentury | Dec 28, 2019
Financial News

Elpiscience’s $100M series B provides path to IPO

Elpiscience hopes a $100 million series B round led by Hyfinity Investments will enable the company to expand its immuno-oncology pipeline and provide enough runway to carry it to an IPO, Ming Fang, head of...
BioCentury | Nov 22, 2019
Preclinical News

Nov. 21 Preclinical Quick Takes: Excision applies CRISPR editing to herpes, John Cunningham viruses; plus Caribou, Oligomerix, Kymab and Gladstone-Boston Univer

...In a preclinical proof of concept study, application of in silico predictions for ROCK1 and CDH1...
...cells. Targets: Cas3 - CRISPR-associated protein 3; Cas9 - CRISPR-associated protein 9; CDH1 (CD324) - E-cadherin...
BioCentury | Aug 2, 2019
Distillery Techniques

Genetic biomarkers for anorexia nervosa

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: SNPs; gene profiling SNPs in eight genomic regions could predict risk of anorexia nervosa. The loci were identified in a meta-analysis of 33 genome-wide association studies (GWAS) covering 16,992 anorexic patients...
BioCentury | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Apr 10, 2019
Distillery Therapeutics

UBR7 and CDH4 as targets for triple-negative breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest UBR7 or its downstream mediator CDH4 could help treat triple-negative breast cancer (TNBC). In tumor samples from patients with TNBC or...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
BioCentury | Jan 24, 2019
Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
BioCentury | Dec 7, 2018
Financial News

Hillhouse backs Elpiscience's $35M round

Elpiscience Biopharma Ltd. (Shanghai, China) raised $35 million in a series A+ round led by Hillhouse Capital Management. Existing investor Lilly Asia Ventures and CDH Investments also participated in the round. Elpiscience is stocking its...
Items per page:
1 - 10 of 162